New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 2, 2014
10:00 EDTURBN, PKE, HP, DRWI, BHI, ABBV, TRGP, ORCL, ETP, CP, BRGYY, WBMD, PTEN, LMCA, LLY, BAC, ALUOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: AbbVie (ABBV) upgraded to Overweight from Equal Weight at Barclays... Alcatel-Lucent (ALU) upgraded to Overweight from Neutral at JPMorgan... BG Group (BRGYY) upgraded to Buy from Hold at Canaccord... Baker Hughes (BHI) upgraded to Neutral from Sell at Guggenheim... Bank of America (BAC) upgraded to Buy from Hold at Deutsche Bank... Canadian Pacific (CP) upgraded to Outperformer from Sector Performer at CIBC... DragonWave (DRWI) upgraded to Buy from Neutral at H.C. Wainwright... Eli Lilly (LLY) upgraded to Equal Weight from Underweight at Barclays... Energy Transfer Partners (ETP) upgraded to Outperform at Wells Fargo... Helmerich & Payne (HP) upgraded to Neutral from Sell at Guggenheim... Liberty Media (LMCA) upgraded at Morgan Stanley... Men's Wearhouse (MW) upgraded at Stifel... Oracle (ORCL) upgraded to Overweight from Neutral at Atlantic Equities... Park Electrochemical (PKE) upgraded to Buy from Hold at Needham... Patterson-UTI Energy (PTEN) upgraded to Neutral from Sell at Guggenheim... Targa Resources (TRGP) upgraded to Conviction Buy from Buy at Goldman... Urban Outfitters (URBN) upgraded to Outperform from Neutral at Macquarie... WebMD (WBMD) upgraded at Stifel.
News For ABBV;ALU;BRGYY;BHI;BAC;CP;DRWI;LLY;ETP;HP;LMCA;ORCL;PKE;PTEN;TRGP;URBN;WBMD From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | all recent news | >>
March 17, 2015
17:06 EDTORCLOracle up 3.38% after reporting Q3 financial results
Subscribe for More Information
17:05 EDTORCLOracle Q3 Software and Cloud revenue up 7% in constant currency
Subscribe for More Information
16:09 EDTORCLOracle says total Cloud SaaS, PaaS and IaaS revenues were up 33%
Subscribe for More Information
16:05 EDTORCLOracle raises quarterly dividend 25% to 15c per share
Subscribe for More Information
16:03 EDTORCLOracle says Q3 Software and Cloud revenues up 1% to $7.2B
Subscribe for More Information
16:02 EDTORCLOracle reports Q3 EPS 68c, consensus 68c
Subscribe for More Information
15:18 EDTORCLNotable companies reporting after market close
Notable companies reporting after the market close, with earnings consensus, include Oracle (ORCL), consensus 68c... Adobe (ADBE), consensus 39c.
15:03 EDTORCLWipro takes minority stake in Drivestream
Wipro (WIT) and Drivestream announced that they have signed an agreement to enter into a strategic partnership to build an integrated Cloud Solutions stack for customers. As part of this arrangement, Wipro is investing $5M in Drivestream, a leading Oracle (ORCL) cloud applications systems integrator. This is part of Wipro’s strategic drive to actively participate in the external innovation eco-system, for which the company has set up Wipro Ventures, a $100M fund focused on investing in disruptive start-ups.
13:15 EDTORCLOracle March 43.5 straddle priced for 5.1% movement into Q3
Subscribe for More Information
08:34 EDTBACBank of America reinstated with an Outperform at Raymond James
Subscribe for More Information
08:03 EDTABBVAbbVie to present data from 22 HUMIRA abstracts at AAD
Subscribe for More Information
06:31 EDTABBVStudies find Gilead's hepatitis C drugs cost effective, Reuters says
Subscribe for More Information
March 16, 2015
15:04 EDTABBVPharmacyclics says committee recommends unblinding after primary endpoint met
Subscribe for More Information
12:36 EDTORCLOracle March volatility increases into Q3 and outlook
Subscribe for More Information
10:22 EDTBACBank of America February default rate 2.98% vs. 2.93% last month
Reports February delinquency rate 1.86% vs. 1.83% last month.
10:14 EDTURBNOptions with decreasing implied volatility
Options with decreasing implied volatility: EXPR ULTA SGMS QIHU BKS PAY URBN AGN AGNC
09:01 EDTCPCanadian Pacific renews share repurchase program
Subscribe for More Information
08:01 EDTTRGPTarga Resources added to Top Picks List at UBS
UBS added Targa Resources (TRGP) to its Top Picks List as they believe the combined models of it and Targa Resources Partners (NGLS) will provide new growth opportunities, but also increased commodity exposures. As a result, UBS maintains its Buy rating but lowers its price target to $118 from $127 on Targa Resources shares.
07:32 EDTORCLUBM Tech to hold a conference
Enterprise Connect 2015 is being held in Orlando, Florida on March 16-19.
07:27 EDTLLYBiodel BIOD-961 Phase 1 clinical trial meets primary efficacy endpoint
Biodel (BIOD) announced positive preliminary results from Study 6-101, a Phase 1 clinical trial comparing Biodel's lyophilized glucagon formulation BIOD-961, designed for use in a proprietary Glucagon Emergency Management, or GEM, auto-reconstitution device, to Eli Lilly's (LLY) Glucagon Emergency Rescue Kit and Novo Nordisk's GlucaGen HypoKit, which are marketed for the treatment of severe hypoglycemia. Study 6-101 was a randomized, single-center, double blind, six-period cross over study in 15 healthy volunteers who received each glucagon administered subcutaneously, or SC, and intramuscularly, or IM, in a randomized treatment sequence. The objectives of the study were to compare the pharmacokinetic, or PK, profiles, the pharmacodynamic, or PD, glucose, responses, and the PK/PD relationships of IM and SC dosing, as well as to assess safety profiles of the three test glucagons. Study 6-101 was a Phase 1 randomized, single-center, double blind, six-period cross over study designed to evaluate the PK and PD profiles of BIOD-961 compared to marketed glucagon formulations manufactured by Eli Lilly and Novo Nordisk. BIOD-961 is a lyophilized glucagon formulation designed for use in the GEM auto-reconstitution device. On six separate dosing days, each subject received 1 mg of one of the test glucagons delivered either SC or IM. Fifteen normal, healthy subjects were randomized into the study and ten completed all dosings. The objectives of the study were to compare the PK profiles, the PD responses, and the PK/PD relationships of IM and SC dosing, as well as to assess safety profiles of the three test glucagons. These data will facilitate selection of an appropriate marketed glucagon to use as a comparator in the planned pivotal study, in which the primary efficacy endpoint for approval is to demonstrate PK and PD bioequivalence of BIOD-961 to one of the marketed comparators.
1 | 2 | 3 | 4 | 5 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use